Invitation to InDex Pharmaceuticals Capital Markets Day on March 14, 2022

STOCKHOLM, February 15, 2022 /PRNewswire/ — InDex Pharmaceuticals Holding AB (publ) invites investors, analysts and the media to a capital markets day on March 14, 2022. Capital Markets Day will be held at Krügersalen at Kapitel 8, Tändstickspalatset, Västra Trädgårdsgatan 15 at stockholm. Presentations will start at 3:00 p.m. CET with registration starting at 2:30 p.m. CET.

The Capital Markets Day will focus on the ongoing CONCLUDE Phase III study with cobitolimod drug candidate, the market potential of cobitolimod and InDex’s long-term strategies for the commercialization of cobitolimod. Cobitolimod is being developed as a new topical treatment for moderate to severe ulcerative colitis. Cobitolimod has shown, with a low frequency of administration, competitive efficacy and an excellent safety profile in previous clinical studies.

Presentations will be given by members of Index management and contract marketing and sales experts. The program will conclude with a Q&A session and is scheduled to conclude at 5:00 p.m. CET with the opportunity to mingle afterwards.

The Capital Markets Day will be held in English and will be broadcast live on https://tv.streamfabriken.com/index-pharmaceuticals-cmd-2022. A recording will be available later on the Index website.

If you wish to participate physically on site, please register by email at [email protected]

For more information:
Pierre ZerhouniCEO
Telephone: +46 8 122 038 50
Email: [email protected]

Publication
The information has been submitted for publication through the contact person listed above at 1:30 p.m. CET to February 15, 2022.

Cobitolimod in a nutshell
Cobitolimod is a first-in-class Toll-like receptor 9 (TLR9) agonist that can provide an anti-inflammatory effect locally in the large intestine, which can induce mucosal healing and relief of clinical symptoms of ulcerative colitis. Cobitolimod is being evaluated in the phase III CONCLUDE study as a new treatment for moderate to severe ulcerative colitis. Cobitolimod met the primary endpoint of the Phase IIb CONDUCT study and demonstrated an exceptional combination of efficacy and safety. The findings were recently published in the reputable medical journal The Lancet Gastroenterology & Hepatology. Data from four prior placebo-controlled clinical trials support the efficacy and safety demonstrated in the CONDUCT study.

About InDex Pharmaceuticals
InDex is a pharmaceutical development company specializing in immunological diseases for which there is a significant unmet medical need for new treatment options. The company’s lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III CONCLUDE study as a novel treatment for moderate to severe ulcerative colitis, a debilitating chronic inflammation of the large intestine. InDex has also developed a platform of patent-protected discovery-stage substances called DNA-based immunomodulatory sequences (DIMS) that can be used in the treatment of various immunological diseases.

InDex is based on Stockholm, Sweden. The company’s shares (INDEX ticker) are traded on the Nasdaq First North Growth Market Stockholm. Redeye AB with email address [email protected] and telephone number +46 8 121 576 90 is the company’s certified advisor. For more information, please visit www.indexpharma.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/index-pharmaceuticals/r/invitation-to-index-pharmaceuticals–capital-markets-day-on-march-14–2022,c3507074

The following files are available for download: